It has been shown to penetrate muscle and cross the blood-brain-barrier. Before the recent COVID-19 outbreak, most of our employees worked remotely. Our previous ticker symbol was "APRI". We will provide the clinical supply of Trehalose. This program is now known as SLS-007. Upon entry into the UC Regents License Agreement, we paid to The UC Regents $0.1 million. Any of our trademarks could be invalidated or circumvented. Although the phases are usually conducted sequentially, they may overlap or be combined. We may not be able to protect our proprietary or licensed technology in the marketplace. We are a clinical-stage biopharmaceutical company. The development process is expensive, can take many years and has an uncertain outcome. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. Despite the time and expense invested, regulatory approval is never guaranteed. Reimbursement policies may be affected by future healthcare reform measures. The loss of our licenses would have a material adverse effect on our business.